Clin2
NCT05701709Possibly a fitRecruiting

First-in-human test for a new drug in advanced solid cancers

Advanced Solid Tumors

Treatments studied

Part of Cancer clinical trials.

This Phase 1 study tests SHR-A2102, a new cancer medicine, in adults with advanced solid tumors. It mainly looks at safety and how the body handles the drug, and it may help if standard treatments are not working or are not an option.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
395 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You can sign a consent form and agree to follow the study plan.
  • You are age 18 or older and have an advanced or metastatic solid cancer confirmed by a pathology lab test.
  • Your cancer treatment options are limited (you tried standard therapy and it failed/intolerable, or there is no standard option, or you choose not to use standard therapy).
  • A scan must show at least one measurable tumor spot that the study can track.
  • You should be well enough to do daily activities (ECOG 0 to 1) and expected to live at least 3 months.
  • You must not start other cancer treatments or other investigational drugs right before and during this study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06895928Recruiting· Phase 2
Testing SHR-A2102 for advanced solid tumors

This trial tests a new drug called SHR-A2102, alone or with other cancer treatments, for people with advanced solid tumors that haven't responded well to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.

Taiyuan, Shanxi
NCT06417554Recruiting· Phase 1/Phase 2
Study of SHR-A2102 for advanced solid tumors

This trial is testing a new drug, SHR-A2102, either alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy. The goal is to see if it can shrink tumors or slow the cancer's growth.

Beijing, Beijing Municipality
NCT06094556Recruiting· Phase 1
A study of SHR-1826 for advanced solid tumors

This trial tests a new drug called SHR-1826 for people with advanced solid tumors that have not responded to or are no longer helped by standard treatments. It is an early-phase study (Phase 1) to see if the drug is safe and how well it works.

Guangzhou, Guangdong
NCT06618651Recruiting· Phase 1
Study of SHR-3821 for advanced solid tumor cancers

This trial tests a new drug called SHR-3821 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and effective.

Chengdu, Sichuan
NCT06643754Recruiting· Phase 1/Phase 2
Study of a new drug (SHR-3276) for advanced cancers

This trial tests a new drug called SHR-3276 for people with advanced cancers that haven't responded to standard treatments. It aims to see if the drug is safe and works against tumors.

Chongqing, Chongqing Municipality
NCT07231211Recruiting· Phase 1/Phase 2
Testing SHR-4610 for advanced solid tumors

This trial tests a new drug called SHR-4610 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective, and may be an option if you have a measurable tumor and are generally in good health.

Hangzhou, Zhejiang

Hear when a new Advanced Solid Tumors trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.